LONDON (AP) — The pharma giant AstraZeneca has requested that the European authorization for its COVID-19 vaccine be pulled, according to the EU medicines regulator. In an update on the European ...
“Katie’s immediate family, extended family and wide network of friends are still traumatised by Katie’s unnecessary death from the AstraZeneca Covid-19 vaccine,” her parents said. They ...
In a May 2024 statement, AstraZeneca said: "As multiple, variant Covid-19 vaccines have since been developed, there is a surplus of available updated vaccines. This has led to a decline in demand ...
The US Food and Drug Administration announced Friday that it had advised the makers of the Covid-19 vaccines to formulate their new shots to be a better match for the JN.1 lineage of the ...
The FDA's vaccine advisory panel voted to recommend that this fall’s Covid-19 shots should be updated to target Omicron’s ...
Moderna announced its combination Covid and flu vaccine generated stronger immune responses in older adults in a Phase 3 ...
Misleading Claims on Well-Known Rare Risk of AstraZeneca COVID-19 Vaccine A rare risk of dangerous blood clots associated with the AstraZeneca COVID-19 vaccine was identified and reported in early ...
The most common local adverse event for Moderna's updated COVID-19 vaccine was injection site pain. The submission is based on FDA guidance, which advised that COVID-19 vaccines should be updated ...
In March 2024, AstraZeneca requested that the authorization for their COVID-19 vaccine be withdrawn by the European Medicines Agency. On May 7, 2024, the company began to withdraw the vaccine ...
June 7 (Reuters) - The U.S. health regulator on Friday advised COVID-19 vaccine manufacturers that new shots for the fall 2024 campaign should target the JN.1 variant that was dominant earlier ...
For most of this year, the JN.1 variant of the coronavirus accounted for an overwhelming majority of COVID-19 cases. But now an offshoot variant called KP.2 is taking off. Thousands believe COVID ...